JOHNSON DAVID LEE 4

What Happened David L. Johnson, a director of Caribou Biosciences (CRBU), was granted a derivative award on February 20, 2026 covering 45,000 shares at a $0.00 price (transaction coded as an award/grant). The filing shows this as a derivative instrument (an option) rather than an open‑market purchase or sale; the reported dollar value exchanged at grant was $0.

Key Details

• Transaction date: 2026-02-20; Transaction type/code: Award/Grant (A), derivative.
• Shares/units granted: 45,000; reported price per share: $0.00; total cash exchanged: $0.
• Vesting: Per the filing footnote, one‑twelfth of the option vests monthly, with full vesting on February 20, 2027, contingent on continued service.
• Shares owned after transaction: Not specified in the excerpt of the filing.
• Filing timeliness: Report filed on 2026-02-20 (period of report 2026-02-20), indicating a timely filing.

Context This was a compensation grant (an option award) not a purchase or sale — no immediate cash changed hands. Grants are common for directors and staff as compensation; the monthly vesting schedule means the award vests over the next year subject to continued service. This Form 4 disclosure is informational about the grant and does not by itself indicate the insider buying or selling shares on the open market.